For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 29,183 | |||
| General and administrative | 12,266 | |||
| Total operating expenses | 41,449 | |||
| Loss from operations | -41,449 | |||
| Interest income | 3,106 | |||
| Change in fair value of redeemable convertible preferred stock tranche liability | 1,526 | |||
| Total other income (expense) | 1,580 | |||
| Loss before income tax | -39,869 | |||
| Federal | 0 | |||
| State | 0 | |||
| Foreign | 0 | |||
| Total current taxes | 0 | |||
| Federal | 8,704 | |||
| State | 1,206 | |||
| Foreign | 0 | |||
| Total deferred taxes | 9,910 | |||
| Valuation allowance | -9,910 | |||
| Income tax provision | 0 | |||
| Net loss | -39,869 | |||
| Basic EPS | -17.98 | |||
| Diluted EPS | -17.98 | |||
| Basic Average Shares | 2,217,104 | |||
| Diluted Average Shares | 2,217,104 | |||
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)